

David R Jayne

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3215078/publications.pdf>

Version: 2024-02-01

61
papers

5,512
citations

172207

29
h-index

161609

54
g-index

65
all docs

65
docs citations

65
times ranked

4691
citing authors

#	ARTICLE	IF	CITATIONS
1	2019 European League Against Rheumatism/American College of Rheumatology Classification Criteria for Systemic Lupus Erythematosus. <i>Arthritis and Rheumatology</i> , 2019, 71, 1400-1412.	2.9	1,098
2	2019 European League Against Rheumatism/American College of Rheumatology classification criteria for systemic lupus erythematosus. <i>Annals of the Rheumatic Diseases</i> , 2019, 78, 1151-1159.	0.5	759
3	Avacopan for the Treatment of ANCA-Associated Vasculitis. <i>New England Journal of Medicine</i> , 2021, 384, 599-609.	13.9	461
4	ANCA-associated vasculitis. <i>Nature Reviews Disease Primers</i> , 2020, 6, 71.	18.1	443
5	Early mortality in systemic vasculitis: relative contribution of adverse events and active vasculitis. <i>Annals of the Rheumatic Diseases</i> , 2010, 69, 1036-1043.	0.5	344
6	Risk factors for relapse of antineutrophil cytoplasmic antibody-associated vasculitis. <i>Arthritis and Rheumatism</i> , 2012, 64, 542-548.	6.7	298
7	BSR and BHPR guideline for the management of adults with ANCA-associated vasculitis. <i>Rheumatology</i> , 2014, 53, 2306-2309.	0.9	246
8	Damage in the anca-associated vasculitides: long-term data from the European Vasculitis Study group (EUVAS) therapeutic trials. <i>Annals of the Rheumatic Diseases</i> , 2015, 74, 177-184.	0.5	214
9	Long-term follow-up of the MAINTAIN Nephritis Trial, comparing azathioprine and mycophenolate mofetil as maintenance therapy of lupus nephritis. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 526-531.	0.5	157
10	Glucocorticoid treatment and damage in the anti-neutrophil cytoplasm antibody-associated vasculitides: long-term data from the European Vasculitis Study Group trials. <i>Rheumatology</i> , 2015, 54, 471-481.	0.9	104
11	Lupus nephritis management guidelines compared. <i>Nephrology Dialysis Transplantation</i> , 2016, 31, 904-913.	0.4	97
12	Effect of rituximab on malignancy risk in patients with ANCA-associated vasculitis. <i>Annals of the Rheumatic Diseases</i> , 2017, 76, 1064-1069.	0.5	95
13	Evaluation of clinical benefit from treatment with mepolizumab for patients with eosinophilic granulomatosis with polyangiitis. <i>Journal of Allergy and Clinical Immunology</i> , 2019, 143, 2170-2177.	1.5	82
14	Rheumatological complications of Covid 19. <i>Autoimmunity Reviews</i> , 2021, 20, 102883.	2.5	73
15	The Relapsing Polychondritis Disease Activity Index: Development of a disease activity score for relapsing polychondritis. <i>Autoimmunity Reviews</i> , 2012, 12, 204-209.	2.5	71
16	Mortality in Wegener's granulomatosis: a bimodal pattern. <i>Rheumatology</i> , 2011, 50, 697-702.	0.9	69
17	Antiendothelial Cell Antibodies in Patients with the Antiphospholipid Syndrome. <i>Autoimmunity</i> , 1991, 11, 1-6.	1.2	66
18	Efficacy and safety of rituximab in the treatment of eosinophilic granulomatosis with polyangiitis. <i>RMD Open</i> , 2019, 5, e000905.	1.8	66

#	ARTICLE	IF	CITATIONS
19	Relapsing polychondritis: a clinical review for rheumatologists. <i>Rheumatology</i> , 2018, 57, 1525-1532.	0.9	65
20	Multicriteria decision analysis process to develop new classification criteria for systemic lupus erythematosus. <i>Annals of the Rheumatic Diseases</i> , 2019, 78, 634-640.	0.5	51
21	Evaluation of the Safety and Efficacy of Avacopan, a C5a Receptor Inhibitor, in Patients With Antineutrophil Cytoplasmic Antibody-Associated Vasculitis Treated Concomitantly With Rituximab or Cyclophosphamide/Azathioprine: Protocol for a Randomized, Double-Blind, Active-Controlled, Phase 3 Trial. <i>IMIR Research Protocols</i> , 2020, 9, e16664.	0.5	50
22	Phase III/IV, Randomized, Fifty-Two-Week Study of the Efficacy and Safety of Belimumab in Patients of Black African Ancestry With Systemic Lupus Erythematosus. <i>Arthritis and Rheumatology</i> , 2022, 74, 112-123.	2.9	47
23	Use of Consensus Methodology to Determine Candidate Items for Systemic Lupus Erythematosus Classification Criteria. <i>Journal of Rheumatology</i> , 2019, 46, 721-726.	1.0	45
24	Comparison of the Phenotype and Outcome of Granulomatosis with Polyangiitis Between UK and Japanese Cohorts. <i>Journal of Rheumatology</i> , 2017, 44, 216-222.	1.0	38
25	European League Against Rheumatism (EULAR)/American College of Rheumatology (ACR) SLE classification criteria item performance. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, 775-781.	0.5	37
26	Recommendations for the management of secondary hypogammaglobulinaemia due to B cell targeted therapies in autoimmune rheumatic diseases. <i>Rheumatology</i> , 2019, 58, 889-896.	0.9	35
27	Performance of the 2019 EULAR/ACR classification criteria for systemic lupus erythematosus in early disease, across sexes and ethnicities. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 1333-1339.	0.5	35
28	Assessment of damage in vasculitis: expert ratings of damage. <i>Rheumatology</i> , 2009, 48, 823-827.	0.9	34
29	[¹⁸ F]-Fluorodeoxyglucose Positron Emission Tomography in the Diagnosis, Treatment Stratification, and Monitoring of Patients with Retroperitoneal Fibrosis: A Prospective Clinical Study. <i>European Urology</i> , 2017, 71, 926-933.	0.9	34
30	Evaluation of PR3-ANCA Status After Rituximab for ANCA-Associated Vasculitis. <i>Journal of Clinical Rheumatology</i> , 2019, 25, 217-223.	0.5	33
31	Current and emerging treatment options in the management of lupus. <i>ImmunoTargets and Therapy</i> , 2016, 5, 9.	2.7	32
32	Medically explained symptoms: a mixed methods study of diagnostic, symptom and support experiences of patients with lupus and related systemic autoimmune diseases. <i>Rheumatology Advances in Practice</i> , 2020, 4, rkaa006.	0.3	31
33	Validation of the EULAR/ERA-EDTA recommendations for the management of ANCA-associated vasculitis by disease content experts. <i>RMD Open</i> , 2017, 3, e000449.	1.8	23
34	Genetic Variants in Antineutrophil Cytoplasmic Antibody-Associated Vasculitis: A Bayesian Approach and Systematic Review. <i>Journal of Clinical Medicine</i> , 2019, 8, 266.	1.0	19
35	Renal manifestations of the antiphospholipid syndrome. <i>Current Rheumatology Reports</i> , 2009, 11, 52-60.	2.1	18
36	Use and reporting of outcome measures in randomized trials for anti-neutrophil cytoplasmic antibody-associated vasculitis: a systematic literature review. <i>Seminars in Arthritis and Rheumatism</i> , 2020, 50, 1314-1325.	1.6	17

#	ARTICLE	IF	CITATIONS
37	Testing for autoimmunity in humans. Toxicology Letters, 2002, 127, 93-100.	0.4	15
38	Con: The use of calcineurin inhibitors in the treatment of lupus nephritis: Table 1. Nephrology Dialysis Transplantation, 2016, 31, 1567-1571.	0.4	15
39	Pericoronary and periaortic adipose tissue density are associated with inflammatory disease activity in Takayasu arteritis and atherosclerosis. European Heart Journal Open, 2021, 1, oeab019.	0.9	15
40	Respiratory subtype of relapsing polychondritis frequently presents as difficult asthma: a descriptive study of respiratory involvement in relapsing polychondritis with 13 patients from a single UK centre. ERJ Open Research, 2021, 7, 00170-2020.	1.1	10
41	Anabolic steroid-induced rhabdomyolysis. British Journal of Hospital Medicine (London, England:) Tj ETQq1 1 0.784314 rgBT /Overlock 1 0.2 9	0.2	9
42	<p>Systemic vasculitis and patient-reported outcomes: how the assessment of patient preferences and perspectives could improve outcomes</p>. Patient Related Outcome Measures, 2019, Volume 10, 37-42.	0.7	9
43	Sequential rituximab and mepolizumab in eosinophilic granulomatosis with polyangiitis (EGPA): a European multicentre observational study. Annals of the Rheumatic Diseases, 2022, 81, 1769-1772.	0.5	9
44	The relapsing polychondritis damage index (RPDAM): Development of a disease-specific damage score for relapsing polychondritis. Joint Bone Spine, 2019, 86, 363-368.	0.8	8
45	A historical essay on detection of anti-neutrophil cytoplasmic antibodies. Nephrology Dialysis Transplantation, 2015, 30 Suppl 1, i8-13.	0.4	7
46	Efficacy of belimumab in two serologically distinct high disease activity subgroups of patients with systemic lupus erythematosus: post-hoc analysis of data from the phase III programme. Lupus Science and Medicine, 2021, 8, e000459.	1.1	7
47	Key issues in the management of patients with systemic lupus erythematosus: latest developments and clinical implications. Therapeutic Advances in Musculoskeletal Disease, 2015, 7, 234-246.	1.2	5
48	Antiphospholipid syndrome. BMJ, The, 2015, 350, h1426-h1426.	3.0	4
49	Comparison of Responsiveness of British Isles Lupus Assessment Group 2004 Index, Systemic Lupus Erythematosus Disease Activity Index 2000, and British Isles Lupus Assessment Group 2004 Systems Tally. Arthritis Care and Research, 2022, 74, 1623-1630.	1.5	3
50	Use of Glomerular CD68+ Cells as a Surrogate Marker for Endocapillary Hypercellularity in Lupus Nephritis. Kidney International Reports, 2022, 7, 841-847.	0.4	3
51	Why do we need a new journal in autoimmunity?. Journal of Autoimmune Diseases, 2004, 1, 1.	1.0	2
52	Opponent's comments. Nephrology Dialysis Transplantation, 2016, 31, 1566-1567.	0.4	1
53	Antineutrophil Cytoplasmic Antibody-associated Vasculitis Management 2020: Where Are We Now?. Journal of Rheumatology, 2021, 48, 479-481.	1.0	1
54	P047 The triple M threat of check-point inhibitors - an emerging overlap syndrome. Rheumatology, 2022, 61, .	0.9	1

#	ARTICLE	IF	CITATIONS
55	Raised Intracranial Pressure Due to Compression of the Jugular Vein in Wegener's Granulomatosis. <i>Neuro-Ophthalmology</i> , 2008, 32, 309-311.	0.4	0
56	Editorial: Advances in SLE – An innovative era for patients and clinicians. <i>Best Practice and Research in Clinical Rheumatology</i> , 2013, 27, 307-308.	1.4	0
57	CHALLENGES IN CONNECTIVE TISSUE DISEASES/VASCULITIS – CHALLENGES IN MANAGING ANTI-PHOSPHOLIPID SYNDROME. <i>Rheumatology</i> , 2017, 56, .	0.9	0
58	An update on current and proposed studies in small vessel vasculitis. <i>Rheumatology</i> , 2018, 57, .	0.9	0
59	Idiopathic aortitis presenting as pyrexia of unknown origin and delirium. <i>British Journal of Hospital Medicine (London, England: 2005)</i> , 2018, 79, 586-587.	0.2	0
60	A series of catastrophic events. <i>Rheumatology Advances in Practice</i> , 2021, 5, .	0.3	0
61	Pre-pregnancy switching from mycophenolate to azathioprine in patients with lupus nephritis: a retrospective outcome analysis. <i>Rheumatology</i> , 2022, 61, .	0.9	0